| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$9,900 ) |
| | 2026 | 2025 | JAGUAR HEALTH INC | 200 PINE ST | SAN FRANCISCO | CA | 94104-2710 | SAN FRANCISCO | USA | R01FD008457 | Clinical field study to evaluate the safety and effectiveness of Canalevia to treat chemotherapy-induced diarrheal in dogs | 000 | 1 | FDA | 12/31/2025 | -$9,900 |
|
| Issue Date FY: 2025 ( Subtotal = $250,000 ) |
| | 2025 | 2025 | JAGUAR HEALTH INC | 200 PINE ST | SAN FRANCISCO | CA | 94104-2710 | SAN FRANCISCO | USA | R01FD008457 | Clinical field study to evaluate the safety and effectiveness of Canalevia to treat chemotherapy-induced diarrheal in dogs | 000 | 1 | FDA | 9/19/2025 | $250,000 |
|
|
